Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 4/20 | 0.71 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4814653 | 1.00 | PDGFRB (0.71) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL372292 | 1.00 | PDGFRB (0.71) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL563573 | 0.83 | PDGFRB (0.73) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL3164863 | 0.83 | PDGFRB (1.00) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL3164867 | 0.83 | PDGFRB (1.00) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL563572 | 0.83 | PDGFRB (0.73) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL5459685 | 0.81 | PDGFRB (0.71) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL7668269 | 0.81 | PDGFRB (0.71) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL9000566 | 0.81 | PDGFRB (0.77) | PDGFRBPDGFRARAB9AKDM4EKMT2A | |
| SCHEMBL9000561 | 0.81 | PDGFRB (0.77) | PDGFRBPDGFRARAB9AKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478653-B1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2014-07-02 | — | — | EP | claimed |
| JP-4795589-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| EP-1501846-B1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LAB (US) | 2009-03-18 | — | — | EP | claimed |
| US-7365174-B2 | Azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-29 | — | — | US | claimed |
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-02-22 | — | — | US | claimed |
| EP-1661904-A1 | NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2006-05-31 | — | — | EP | claimed |
| US-6992069-B2 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2006-01-31 | — | — | US | claimed |
| US-6933283-B2 | 11-deoxy azalide antibacterials | ABBOTT LABORATORIES (US) | 2005-08-23 | — | — | US | claimed |
| EP-1272500-B1 | PROCESS FOR PREPARING 6-O-ALKENYL-SUBSITUTED ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2005-05-04 | — | — | EP | claimed |
| EP-1501847-A2 | 11-DEOXY AZALIDE ANTIBACTERIALS | Abbott Laboratories (US) | 2005-02-02 | — | — | EP | claimed |
| EP-1345953-A2 | KETOLIDE ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2003-09-24 | — | — | EP | claimed |
| US-6590083-B1 | Compounds of given formula; erythromycin derivatives; useful in the treatment of bacterial and protozoal infections and conditions involving gastric motility | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-07-08 | — | — | US | claimed |
| EP-1272500-A2 | PROCESS FOR PREPARING 6-O-ALKENYL-SUBSITUTED ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | claimed |
| CN-1379780-A | Process for preparing 6-o-alkenyl-substituted erythromycin derivatives | ABBOTT LAB (US) | 2002-11-13 | — | — | CN | claimed |
| US-6458771-B1 | SERIES OF KETOLIDE ANTIBACTERIALS IN THE MACROLIDE FAMILY, DRUGS AND INTERMEDIATES, ERYTHROMYCIN ANALOGUES USEFUL IN THE TREATMENT OF BACTERIAL AND PROTOZOAL INFECTIONS AND IN THE TREATMENT OF GASTRIC MOTILITY | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-01 | — | — | US | claimed |
| US-6395710-B1 | CONTROLLING INFECTIONS | KOSAN BIOSCIENCES, INC. | 2002-05-28 | — | — | US | claimed |
| WO-2002032918-A2 | KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-04-25 | — | — | WO | claimed |
| EP-1171447-A2 | KETOLIDE ANTIBACTERIALS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-01-16 | — | — | EP | claimed |
| WO-2000078773-A2 | PROCESS FOR PREPARING 6-O-ALKENYL-SUBSTITUTED ERYTHROMYCIN DERIV ATIVES | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | claimed |
| WO-2000062783-A2 | KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-10-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | BCL6, NR4A1, NR4A2 | PDGFRB 2207/4885PDGFRA 2360/4885RAB9A 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.